Simona Migliozzi

Dr. Simona Migliozzi

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
TMTathiane M. Malta
Tathiane M. Malta
TSThais S. Sabedot
Thais S. Sabedot
NMNatalia S. Morosini
Natalia S. Morosini
IDIndrani Datta
Indrani Datta
LGLuciano Garofano
Luciano Garofano
HNHoutan Noushmehr
Houtan Noushmehr
Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial and recurrent tumors from patients with IDH-wildtype (IDHwt) and IDH-mutant (IDHmut) glioma. IDHwt gliomas showed a stable epigenome over time with relatively low levels of global methylation. The epigenome of IDHmut gliomas showed initial high levels of genome-wide DNA methylation that was progressively reduced to levels similar to those of IDHwt tumors. Integration of epigenomics, gene expression, and functional genomics identified HOXD13 as a master regulator of IDHmut astrocytoma evolution. Furthermore, relapse of IDHmut tumors was accompanied by histologic progression that was associated with survival, as validated in an independent cohort. Finally, the initial cell composition of the tumor microenvironment varied between IDHwt and IDHmut tumors and changed differentially following treatment, suggesting increased neoangiogenesis and T-cell infiltration upon treatment of IDHmut gliomas. This study provides one of the largest cohorts of paired longitudinal glioma samples with epigenomic, transcriptomic, and genomic profiling and suggests that treatment of IDHmut glioma is associated with epigenomic evolution toward an IDHwt-like phenotype. Significance: Standard treatments are related to loss of DNA methylation in IDHmut glioma, resulting in epigenetic activation of genes associated with tumor progression and alterations in the microenvironment that resemble treatment-naïve IDHwt glioma.

8 May 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
DODuarte Mendes Oliveira
Duarte Mendes Oliveira
CLCarmelo Laudanna
Carmelo Laudanna
SMSimona Migliozzi
Simona Migliozzi
PZPietro Zoppoli
Pietro Zoppoli
GSGianluca Santamaria
Gianluca Santamaria
ARAntonia Rizzuto
Antonia Rizzuto
Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing

17 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
DODuarte Mendes Oliveira
Duarte Mendes Oliveira
GSGianluca Santamaria
Gianluca Santamaria
CLCarmelo Laudanna
Carmelo Laudanna
SMSimona Migliozzi
Simona Migliozzi
PZPietro Zoppoli
Pietro Zoppoli
ARAntonia Rizzuto
Antonia Rizzuto
Identification of copy number alterations in colon cancer from analysis of amplicon-based Next generation sequencing data Identification of copy number alterations in colon cancer from analysis of amplicon-based Next generation sequencing data

27 April 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
DODuarte Mendes Oliveira
Duarte Mendes Oliveira
TMTeresa Mirante
Teresa Mirante
CMChiara Mignogna
Chiara Mignogna
MSMarianna Scrima
Marianna Scrima
SMSimona Migliozzi
Simona Migliozzi
ARAntonia Rizzuto
Antonia Rizzuto
// Duarte Mendes Oliveira 1, 6 , Teresa Mirante 1, 6 , Chiara Mignogna 2 , Marianna Scrima 1, 8 , Simona Migliozzi 1 , Gaetano Rocco 3 , Renato Franco 4 , Francesco Corcione 7 , Giuseppe Viglietto 1, 6 , Donatella Malanga 1, 6 and Antonia Rizzuto 5 1 Department of Experimental and Clinical Medicine, University “Magna Graecia”, Catanzaro, Italy 2 Department of Health Sciences, University “Magna Graecia”, Catanzaro, Italy 3 Pathology Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, Naples, Italy 4 Pathology Unit, Second University of Naples, Italy 5 Department of Medical and Surgical Sciences, University “Magna Graecia”, Catanzaro, Italy 6 Interdepartmental Center of Services (CIS), University “Magna Graecia”, Catanzaro, Italy 7 UOC Chirurgia Generale, Azienda Ospedaliera dei Colli, Napoli, Italy 8 Biogem scarl, Institute of Genetic Research, Ariano Irpino (AV), Italy Correspondence to: Giuseppe Viglietto, email: viglietto@unicz.it Donatella Malanga, email: malanga@unicz.it Keywords: solid tumors; oncomine focus assay; copy number variation; gene fusions Received: December 09, 2017 Accepted: April 05, 2018 Published: April 27, 2018 ABSTRACT In this study, we have set-up a routine pipeline to evaluate the clinical application of Oncomine™ Focus Assay, a panel that allows the simultaneous detection of single nucleotide hotspot mutations in 35 genes, copy number alterations (CNAs) in 19 genes and gene fusions involving 23 genes in cancer samples. For this study we retrospectively selected 106 patients that were submitted to surgical resection for lung, gastric, colon or rectal cancer. We found that 56 patients out of 106 showed at least one alteration (53%), with 47 patients carrying at least one relevant nucleotide variant, 10 patients carrying at least one CNA and 3 patients carrying one gene fusion. On the basis of the mutational profiles obtained, we have identified 22 patients (20.7%) that were potentially eligible for targeted therapy. The most frequently mutated genes across all tumor types included KRAS (30 patients), PIK3CA (16 patients), BRAF (6 patients), EGFR (5 patients), NRAS (4 patients) and ERBB2 (3 patients) whereas CCND1, ERBB2, EGFR and MYC were the genes most frequently subjected to copy number gain. Finally, gene fusions were identified only in lung cancer patients and involved MET [MET(13)–MET(15) fusion] and FGFR3 [FGFR3(chr 17)–TACC3(chr 11)]. In conclusion, we demonstrate that the analysis with a multi-biomarker panel of cancer patients after surgery, may present several potential advantages in clinical daily practice, including the simultaneous detection of different potentially druggable alterations, reasonable costs, short time of testing and automated interpretation of results. Duarte Mendes Oliveira1,6, Teresa Mirante1,6, Chiara Mignogna2, Marianna Scrima1,8, Simona Migliozzi1, Gaetano Rocco3, Renato Franco4, Francesco Corcione7, Giuseppe Viglietto1,6, Donatella Malanga1,6 and Antonia Rizzuto5 1Department of Experimental and Clinical Medicine, University “Magna Graecia”, Catanzaro, Italy 2Department of Health Sciences, University “Magna Graecia”, Catanzaro, Italy 3Pathology Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, Naples, Italy 4Pathology Unit, Second University of Naples, Italy 5Department of Medical and Surgical Sciences, University “Magna Graecia”, Catanzaro, Italy 6Interdepartmental Center of Services (CIS), University “Magna Graecia”, Catanzaro, Italy 7UOC Chirurgia Generale, Azienda Ospedaliera dei Colli, Napoli, Italy 8Biogem scarl, Institute of Genetic Research, Ariano Irpino (AV), Italy Correspondence to: Giuseppe Viglietto, email: viglietto@unicz.it Donatella Malanga, email: malanga@unicz.it Keywords: solid tumors; oncomine focus assay; copy number variation; gene fusions Received: December 09, 2017 Accepted: April 05, 2018 Published: ABSTRACT In this study, we have set-up a routine pipeline to evaluate the clinical application of Oncomine™ Focus Assay, a panel that allows the simultaneous detection of single nucleotide hotspot mutations in 35 genes, copy number alterations (CNAs) in 19 genes and gene fusions involving 23 genes in cancer samples. For this study we retrospectively selected 106 patients that were submitted to surgical resection for lung, gastric, colon or rectal cancer. We found that 56 patients out of 106 showed at least one alteration (53%), with 47 patients carrying at least one relevant nucleotide variant, 10 patients carrying at least one CNA and 3 patients carrying one gene fusion. On the basis of the mutational profiles obtained, we have identified 22 patients (20.7%) that were potentially eligible for targeted therapy. The most frequently mutated genes across all tumor types included KRAS (30 patients), PIK3CA (16 patients), BRAF (6 patients), EGFR (5 patients), NRAS (4 patients) and ERBB2 (3 patients) whereas CCND1, ERBB2, EGFR and MYC were the genes most frequently subjected to copy number gain. Finally, gene fusions were identified only in lung cancer patients and involved MET [MET(13)–MET(15) fusion] and FGFR3 [FGFR3(chr 17)–TACC3(chr 11)]. In conclusion, we demonstrate that the analysis with a multi-biomarker panel of cancer patients after surgery, may present several potential advantages in clinical daily practice, including the simultaneous detection of different potentially druggable alterations, reasonable costs, short time of testing and automated interpretation of results.

1 July 2021 in Cancer Research
Verified
Journal Article
Closed access
LGLuciano Garofano
Luciano Garofano
SMSimona Migliozzi
Simona Migliozzi
YOYoung Taek Oh
Young Taek Oh
FDFulvio D'Angelo
Fulvio D'Angelo
RNRyan D. Najac
Ryan D. Najac
AIAntonio Iavarone
Antonio Iavarone
Transcriptomic classification has been used to molecularly characterize glioblastoma (GBM) but has failed to predict survival and inform on pharmacologic vulnerability. Here, we developed a computational approach for the unbiased identification of the core biological pathways that optimally classify individual glioma cells and bulk tumors. Using single cell RNA-sequencing data from 36 high-grade gliomas, we uncovered four transcriptional states that exist along two evolutionary axes, a metabolic axis including mitochondrial and glycolytic/pluri-metabolic and a neurodevelopmental axis including proliferative/progenitor and neuronal states. The activation of the same set of biological pathways independently stratified primary GBM into four subtypes, among which the mitochondrial subgroup was associated with the most favorable clinical outcome. By integrating genomic, transcriptomic, DNA methylation, microRNA and proteomics analysis, we found that mitochondrial GBM was enriched with coherent gain-of-function of mitochondrial genes and loss-of-function alterations targeting glycolysis and alternative metabolic programs, suggesting that this subgroup may fail to produce compensatory metabolism. Mitochondrial GBM relied exclusively on oxidative phosphorylation for energy production whereas the glycolytic/pluri-metabolic subtype was sustained by concurrent activation of multiple metabolic fluxes including aerobic glycolysis, amino acid consumption and lipid synthesis and storage. Deletion of SLC45A1, a gene coding for a glucose-H+ symporter on chromosome 1p36.23, emerged as the truncal genetic alteration most significantly associated with mitochondrial GBM. Reintroduction of SLC45A1 in mitochondrial GBM cells harboring SLC45A1 gene deletion induced cytoplasmic acidification, loss of cell fitness and growth arrest. The strict dependency of mitochondrial GBM on mitochondrial respiration was associated with excessive generation of reactive oxygen species and unique sensitivity to inhibitors of oxidative phosphorylation. Collectively, this work presents a classification of GBM that informs clinical outcome and identifies patients who are more likely to benefit from therapies targeting metabolic vulnerabilities. Citation Format: Luciano Garofano, Simona Migliozzi, Young Taek Oh, Fulvio D'Angelo, Ryan D. Najac, Aram Ko, Brulinda Frangaj, Francesca Pia Caruso, Kai Yu, Jinzhou Yuan, Wenting Zhao, Anna Luisa Di Stefano, Franck Bielle, Tao Jiang, Peter Sims, Mario L. Suvà, Fuchou Tang, Xiao-Dong Su, Michele Ceccarelli, Marc Sanson, Anna Lasorella, Antonio Iavarone. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 97.

1 November 2023 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
BABruno Adabbo
Bruno Adabbo
SMSimona Migliozzi
Simona Migliozzi
LGLuciano Garofano
Luciano Garofano
YOYoung Taek Oh
Young Taek Oh
SGSakir H Gultekin
Sakir H Gultekin
AIAntonio Iavarone
Antonio Iavarone
Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumor, with no curative treatment options. Multiple studies have characterized at single cell resolution the GBM as being composed of transcriptional cell states interconnected with components in the tumor immune microenvironment (TME). Our group proposed and validated the first single cell guided functional classification of GBM in four tumor-intrinsic cell states which informed clinical outcome and delivered therapeutic options. However, single cell technologies lack the spatial relationships among the cell states of GBM and between GBM cell states and TME. Spatially resolved transcriptomic technologies are emerging as powerful tools to reconstruct the spatial architecture of a tissue. We performed spatial transcriptomics of multicellular regions of interest (ROI) in 8 IDH wild-type GBM with both CosMx Spatial Molecular Imager, which analyzes 1,000 RNA probes and 64 proteins at single cell resolution, and GeoMx Digital Spatial Profiler which profiles the whole transcriptome (~18,000 genes) at ROI resolution. We integrated the two platforms to define single cell states and non-malignant cells and developed a computational deconvolution approach for CosMx spatial data which utilized GeoMx ROI resolved transcriptomic profiles as a-priori information to predict cell type abundances. Spatial deconvolution of CosMx derived single cells revealed spatial segregation of the tumor cell clones and cellular states and highlighted recurrent patterns of cell states, distinct TME cell types associated with coherent histopathological features across multiple samples. Our studies established a scalable approach to resolve the transcriptional heterogeneity of GBM and reconstruct the architecture of GBM cell states and tumor microenvironment.